First long-term outcome data for the MicraVR™ transcatheter pacing system: data from the largest prospective German cohort.

ABSTRACT:

Aims

The MicraVR™ transcatheter pacing system (TPS) has been implemented into clinical routine for several years. The primary recipients are patients in need for VVI pacing due to bradycardia in the setting of atrial fibrillation (AF). Implantation safety and acute success have been proven in controlled studies and registries. So far only few long-term real-life data on TPS exist. We report indication, procedure and outcome data from two high-volume implanting German centers.

Methods

Between 2016 and 2019, 188 (of 303) patients were included. During follow-up (FU), TPS interrogation was performed after 4 weeks and thereafter every 6 months.

Results

Indication for TPS implantation in 159/188 (85%) patients was permanent or intermittent AV block III° in the setting of a

SUBMITTER: Sultan A 

PROVIDER: S-EPMC11420340 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature